Novo Nordisk (NVO-NYSE, $109.33) Raises 2021 Guidance by 15%, Based on Back Half of 2021 Strength.

This pre-announcement represents, what I consider to be, a significant departure from prior financial reports. Typically, management at NVO provides any guidance increases concurrent with the release of a financial report. This notification has taken place prior to the fiscal release.

https://ml-eu.globenewswire.com/Resource/Download/122e5ecc-d58a-4137-8935-6ce9ab084bfa

Will Wegovy become the next pharmaceutical brand that is considered “buzz-worthy”? It appears possible.

Posted in Open Blog

Leave a Reply

Recent Comments